Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORIA: Adagloxad simolenin in TNBC
NCT03562637Phase 3Active, not recruiting
- Sponsor
- OBI Pharma
- Start
- Dec 2018
- Primary completion
- Dec 2025
- Modality
- Therapeutic Vaccines, Split/Subunit Vaccines
- Countries
- 13
01
Overview
A Phase 3 trial of adagloxad simolenin in triple-negative breast cancer (TNBC), sponsored by OBI Pharma. Started Dec 2018; status: active, not recruiting.
02
Drugs
adagloxad simolenin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03562637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03562637.